key: cord-0429044-k3itl7ss
authors: Chen, Haizhang; Maul-Pavicic, Andrea; Holzer, Martin; Salzer, Ulrich; Chevalier, Nina; Voll, Reinhard E.; Hengel, Hartmut; Kolb, Philipp
title: FcγR responses to soluble immune complexes of varying size: A scalable cell-based reporter system
date: 2020-11-16
journal: bioRxiv
DOI: 10.1101/2020.11.11.378232
sha: 5fbf70296f7c188ecb438c36f93e806052c56c35
doc_id: 429044
cord_uid: k3itl7ss

Fcγ-receptor (FcγR) activation by antibody derived soluble immune complexes (sICs) is a major contributor to inflammation in autoimmune diseases such as systemic lupus erythematosus (SLE). A robust and scalable test system allowing for the detection and quantification of sICs with regard to receptor activation is missing. We developed a comprehensive cell-based reporter system capable of measuring the sIC-mediated activation of human and mouse FcγRs individually. We show that compared to human FcγRs IIB and III, human FcγRs I and IIA lack sensitivity to sICs. The assay enables measurement of FcγR activation in response to sIC size and demonstrates a complete translation of the Heidelberger-Kendall precipitation curve to FcγR responsiveness. The assay also proved useful to quantify sICs-mediated FcγR activation using sera from SLE patients and mouse models of lupus and arthritis. Thus, in clinical practice, our assay might be employed as a diagnostic tool to measure FcγR activation as a biomarker for disease activity in immune-complex mediated disease.

puromycin selection is shown in Fig. 1A . Activation of the reporter cells is measured by 127 quantification of mouse IL-2 (mIL-2) secretion into the cell culture supernatant using an anti-128 IL-2 sandwich ELISA as described previously ( There are only few commercially available antibody-antigen pairs that meet both the above 174 mentioned high grade purity requirements while also allowing for multimeric sIC formation. We 175 focused on three pairs of multivalent antigens and their respective mAbs that were available 176 in required amounts enabling large-scale titration experiments; trimeric rhTNFα:IgG1 infliximab 177 (TNFα:Ifx), dimeric rhVEGFA: IgG1 bevacizumab (VEGFA/Bvz) and dimeric rhIL-5: IgG1 178 mepolizumab (IL-5/Mpz). As lymphocytes express TNFα-receptors I and II while not 179 expressing receptors for IL-5 or VEGFA, we tested whether our mouse lymphocyte derived 180 BW5147 thymoma reporter cell line is sensitive to high concentrations of rhTNFα. Toxicity 181 testing revealed that even high concentrations up to 76.75 nM rhTNFα did not affect viability 182 of reporter cells (Fig. S1 ). Next, we measured the dose-dependent activation of human FcγRs 183 comparing immobilized IgG to soluble ICs using the FcγR reporter cell panel (Fig. 3) . Three different multivalent ultra-pure antigens (Ag) mixed with respective therapy-grade mAbs 202

were used to form sICs as indicated for each set of graphs (top to bottom cytometry, we observed a differential activation pattern depending on ICs being soluble or 219 immobilized at equal molarity (Fig. 4A) . We chose IL-5/Mpz sICs as NK cells do not express 220 the IL-5 receptor. While MIP1-β responses were comparable between the two triggers, 221 degranulation (CD107a) and TNFα responses showed a trend towards lower activation by sICs 222 compared to immobilized IgG (Mpz). Strikingly, IFNγ responses were significantly weaker 223 when NK cells were incubated with sICs compared to immobilized IgG. In order to confirm this 224 hierarchy of responses and to enhance the overall low activation by Fcγ compared to the PMA 225 control, we changed the IC setup by generating reverse-orientation sICs consisting of human 226

FcγR-specific mAbs and goat-anti-mouse IgG F(ab) 2 fragments. NK cell activation by reverse 227 sICs was compared to NK cell activation by immobilized FcγR specific mAbs (Fig. 4B) . Here, 228

we not only confirm our previous observations regarding MIP-1β and IFNγ, but we also confirm 229 significantly lower TNFα and CD107a responses towards soluble complexes compared to 230 immobilized mAbs. Importantly, these experiments validate that sICs readily activate primary 231 NK cells and induce immunological effector functions. As in 10% of the population NK cells 232 express FcγRIIC (Breunis et al., 2008; Metes et al., 1998) , we also tested if this receptor plays 233 a role in our measurements. Using the same three donors and an FcγRII specific mAb as 234 described above, we did not observe an FcγRII-mediated response. Accordingly, we conclude 235 that FcγRIIC expression did not play a role in our experiments (Fig. 4C ). Taken together, we 236

show that multivalent but not dimeric soluble immune complexes govern primary NK cell 237 response and FcγRIIIA/B activation ( Fig. 2A) . 238 complexed FcγRIII-specific mAb (reverse sICs), immobilized IgG of non-FcγRIII-specificity 247 (isotype control) or soluble F(ab) 2 complexed isotype control (all at 1µg, 10 6 cells). Incubation 248

with PMA and Ionomycin served as a positive control. Incubation with medium alone served 249 as a negative control. C) As in B using an FcγRII-specific mAb. NK cells from the tested donors 250 in this study do not react to FcγRII activation. 251 252 253

We observed that the dimeric sIC CD20:Rtx completely failed to activate our reporter cells, 255 while potentially larger sICs based on multimeric antigens showed an efficient dose-dependent 256

FcγR activation. In order to determine whether the assay is able to respond to changes in sIC 257 size, we tested cross-titrated amounts of antibody (mAb, infliximab, Ifx) and antigen (Ag, 258 rhTNFα). To this end, the reporter cells were incubated with sIC of different mAb:Ag ratio by 259 fixing one parameter and titrating the other. According to the Heidelberger-Kendall precipitation 260 curve (Heidelberger and Kendall, 1929) describing sIC size as being dependent on the mAb:Ag 261 ratio, this should result in varying sIC sizes as an excess of either antigen or antibody results 262 in the formation of smaller complexes compared to the large molecular complexes formed at 263 around equal molarity. Changes in sIC size due to a varying mAb:Ag ratio were quantified 264 using asymmetrical flow-field flow fractionation (AF4) ( Fig. 5A and Table S1 ). precipitation curve with a functional read-out. A) infliximab (mAb) and rhTNFα (Ag) were 293 mixed at different ratios (17 µg total protein, calculated from monomer molarity) and analysed 294 via AF4. sIC size is maximal at a 1:3 ratio of mAb:Ag and reduced when either mAb or Ag are 295

given in excess. <M> w = mass-weighted mean of the molar mass distribution. Three 296 independent experiments. Error bars = SD. Data taken from Table S1. One complete run 297 analysis is shown in Fig. S2 . B) FcγR BW5147 reporter cell activation is sensitive to sIC size. 298 sICs of different size were generated by cross-titration according to the AF4 determination. 299

Reporter cells were incubated with fixed amounts of either mAb (infliximab, left) or Ag (rhTNFα, 300 right) and titrated amounts of antigen or antibody, respectively. X-Axis shows titration of either 301 antigen or antibody, respectively (TNFα calculated as monomer). IL-2 production of reporter 302 cells shows a peak for FcγRIIB/C and FcγRIIIA/B activation at an antibody:antigen ratio 303 between 1:2 and 1:4. FcγRs I and IIA show no activation towards sICs in line with previous 304

observations. Two independent experiments. Error bars = SD. C) Primary NK cells purified by 305 negative selection magnetic bead separation from three different donors were incubated with 306 cross-titrated sICs as in A. NK cells were measured for MIP-1β expression (% positivity). 307

Incubation with PMA and Ionomycin served as a positive control. Incubation with medium alone 308 served as a negative control. Measured in technical replicates. Error bars = SD. 309

In order to apply the assay to a clinically relevant condition we measured circulating sICs 311 present in the serum of SLE patients with variable disease activity. Sera from 4 healthy donors 312 and 25 SLE patients were investigated for FcγRIIIA/B and FcγRIIB/C activation. Reporter cells 313 produced IL-2 in response to patient sera in a dose-dependent manner (shown exemplarily for 314 one group of SLE patients in Fig. 6A) , which was not the case when sera from healthy controls 315 were tested. Consistent with the observation that FcγRI and FcγRIIA do not respond to 316 synthetic sICs, reporter cells expressing these receptors did also not respond to the tested 317 serum samples. While this reaction pattern already indicated that sICs are the reactive 318 component measured in SLE patients' sera, we further demonstrate that FcγRIIIA/B and 319

FcγRIIB/C activation depends on the presence of serum ICs by analyzing patient serum before 320 and after polyethylene glycol (PEG) precipitation of sICs (Fig. 6B) anti-dsDNA titers and C3d (p=0.0078 and p=0.0118, respectively). FcγRIIB/C on the other 328 hand showed no significant correlation with either biomarker. We assume this may be due to 329 the influence of IgG sialyation found to be reduced in active SLE (Vuckovic et al., 2015) . 330

Generally, de-sialylation of IgG leads to stronger binding by the activating receptors FcγRI, 331

FcγRIIA and FcγRIII while it reduces the binding affinity of the inhibitory FcγRIIB (Kaneko et 332 al., 2006 arthritis (K/BxN) mice with active disease. The reporter assay was performed as described 363 above. We chose to measure the stimulation of the activating receptors, mFcγRIII and 364 mFcγRIV, that correspond to human FcγRIII and show a comparable cellular distribution and 365 immune function (Bruhns and Jonsson, 2015) . Incubation with synthetic sICs generated from 366 rhTNFα and mouse-anti-hTNFα IgG1 showed both of the mFcγR reporter cells to be 367 responsive to sICs (Fig. 7A) . Parental BW5147 cells expressing no FcγRs served as a negative 368

control. The sera of three mice per group were analysed and compared to sera from wildtype 369 C57BL/6 mice, which served as a negative control. We consistently detected mFcγR activation 370 by sera from K/BxN or NZB/WF1 compared to BL6 mice (Fig. 7B) . While the mFcγRIII 371 responses were generally high and similar between K/BxN and NZB/WF1 mice, we found a 372 lower and more variable mFcγRIV responsiveness. We assume this might be explained by 373 differences in mFcγR affinity to mouse IgG subclasses. While mFcRIII binds IgG1, IgG2a and 374

IgG2b with comparable affinity, IgG1 is not detected by mFcRIV (Bruhns and Jonsson, 2015) . 375

Further, we found that the response of mFcγRIV-expressing reporter cells shows no strict 376 dose-dependency. This effect was more pronounced for NZB/WF1 compared to K/BxN mice. 377

In addition, in this case we assume an influence of factors such as glycosylation patterns or 378 subclass composition, not further addressed here. Nevertheless, the assay enables the 379 reliable detection of sICs in sera of mice with immune-complex mediated diseases making it a 380 promising novel tool to monitor sICs as a biomarker of disease activity. 381 We provide for the first time a simultaneous functional and biophysical assessment of the 451 paradigmatic Heidelberger-Kendall precipitation curve (Heidelberger and Kendall, 1929) . 452

While previous work revealed that large and small sICs show differential impact on IL-6 453 production in PBMCs (Lux et al., 2013) , the dynamics of FcγR activation resulting from 454 constant changes in sIC size have not been explored in great detail yet. This was achieved in 455 this study by directly analyzing native molecules via AF4 (Fig. 5A, Fig. S2 , Table S1 ). Our data 456 reveal that sIC size is indeed governed by antibody:antigen ratios covering a wide range of 457 sizes up to several megadaltons. In the presence of increasing amounts of antibody or antigen 458 deviating from an optimal antibody:ratio, sIC size steadily decreases. 

We found that FcγRI is not activated by sICs in our assay. We assume that FcγRI activation 469 by sICs might require a native cellular environment given that a major function is the uptake of 470

ICs even in the absence of a signaling motif (Indik et al., 1994) . However, we find that FcγRI 471 ectodomains alone are not responsive to sICs indicating a different cross-linking threshold for 472

FcγRI possibly linked to it being the only high-affinity FcγR with three extracellular Ig domains 473 compared to the two domains found in other FcγRs. This reflects a general consideration 474 regarding the reporter system. While providing a robust and unified read-out using a scalable 475 cell-based approach, the assay is not able to reflect native immune cell functions governed by 476 cell specific signalling cascades. The major advancements of this reporter system include i) a 477 higher accuracy regarding FcγR activation compared to strict affinity measurement, ii) an sIC 478 size dependent quantification of FcγR responsiveness and iii) the identification of FcγR 479 activating sICs in autoimmunity but also infection. Finally, this scalable, sensitive and robust were not available and difficult to calculate as the exact stoichiometry is not known. An 580 extinction coefficient of 1.450 mL/(mg cm) was used for calculating the molar masses of all 581

ICs. Especially in the case of ICs rich in TNFα, the true coefficients should be lower, and the 582 molar masses of these complexes are overestimated by not more than 14 %. The determined 583 molar masses for TNFα-rich complexes are therefore biased but the observed variations in 584 molar mass for the different ICs remain valid. The mass-weighted mean of the distribution of 585 molar masses for each sample was calculated using the ASTRA 7 software package (Wyatt). Table S1. Analysis of the molar mass distribution of ICs from AF4 data. 849

For a given elution time, the AF4 profiles provide the concentration (UV) at which a given molar 850 mass (MALS) of a protein is present in the sample. The molar mass distribution of Ifx, TNFα 851

and their immune complexes (sICs) was obtained by plotting the cumulative frequency as a 852

function of molar mass. For a selected range of molar masses, a mass-weighted mean value 853 (<M w >) was calculated. All detected molar masses were selected in the case of Ifx and TNFα 854 whereas only molar masses larger than the maximal molar mass found for Ifx were assigned 855

to sICs. The table shows the range of assigned molar masses and the calculated <M w > for 856 each AF4 run (n = 3). 857 858

Lupus-prone (NZBxNZW)F1 mice (NZB/WF1) were generated by crossing NZB/BlNJ mice with 613

NZW/LacJ mice, purchased from The Jackson Laboratory. KRNtg mice were obtained from F

C57BL/6 mice (BL/6) and NOD/ShiLtJArc (NOD/Lt)

KRNtgxNOD)F1 mice 617 (K/BxN) were obtained by crossing KRNtg mice and NOD/Lt mice. All mice were housed in a 618 12-h light/dark cycle, with food and water ad libitum. Mice were euthanized and blood collected 619 for serum preparation from 16 weeks old BL/6 animals

The Human FcgammaRII 643 (CD32) Family of Leukocyte FcR in Health and Disease

C1q-bearing immune 645 complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis 646 sera and synovial fluids

648 CD28 (null) CD4 T-cell expansions in autoimmune disease suggest a link with 649 cytomegalovirus infection

Immune complex-induced interleukin-6, interleukin-651 10 and prostaglandin secretion by human monocytes: A network of pro-and anti-652 inflammatory cytokines dependent on the antigen:antibody ratio

Sweet and sour: the role of glycosylation for the 655 anti-inflammatory activity of immunoglobulin G. Current topics in microbiology and 656 immunology

Signaling by 658 Antibodies: Recent Progress

Copy number variation of the activating FCGR2C 661 gene predisposes to idiopathic thrombocytopenic purpura

Properties of mouse and human IgG receptors and their contribution to 663 disease models

Specificity and affinity of human Fc gamma receptors and their 666 polymorphic variants for human IgG subclasses

Specificity and affinity of human Fcgamma receptors and their 669 polymorphic variants for human IgG subclasses

Mouse and human FcR effector functions

674 Human cytomegalovirus Fcgamma binding proteins gp34 and gp68 antagonize 675 Fcgamma receptors I, II and III

A novel assay for detecting virus-678 specific antibodies triggering activation of Fcgamma receptors

Clustering of the High-Affinity Fc 681 Receptor for Immunoglobulin-G (Fc-Gamma-Ri) Results in Phosphorylation of Its 682 Associated Gamma-Chain

Insoluble and soluble immune 684 complexes activate neutrophils by distinct activation mechanisms: changes in 685 functional responses induced by priming with cytokines

Insoluble and soluble immune 687 complexes activate neutrophils by distinct activation mechanisms: changes in 688 functional responses induced by priming with cytokines

Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin 690 Fc receptor signaling

692 Sustained Immune Complex-Mediated Reduction in CD16 Expression after 693 Vaccination Regulates NK Cell Function

Tyrosine phosphorylation of the gamma 698 subunit of Fc gamma receptors, p72syk, and paxillin during Fc receptor-mediated 699 phagocytosis in macrophages

The function of 701 Fcgamma receptors in dendritic cells and macrophages

A Quantitative Study of the Precipitin Reaction 703 between Type Iii Pneumococcus Polysaccharide and Purified Homologous Antibody

FcRn is a CD32a coreceptor that 708 determines susceptibility to IgG immune complex-driven autoimmunity

The high affinity Fc gamma receptor (CD64) induces 711 phagocytosis in the absence of its cytoplasmic domain: the gamma subunit of Fc 712 gamma RIIIA imparts phagocytic function to Fc gamma RI

Anti-inflammatory activity of 714 immunoglobulin G resulting from Fc sialylation

Promote B Cell Memory by Inducing BAFF

The Syk protein tyrosine kinase is essential for Fc gamma receptor 720 signaling in macrophages and neutrophils

Inside-Out Control of Fc-Receptors

Systemic lupus erythematosus: 723 prototype of immune complex nephritis in man

726 Identification and Functional Characterization of a Novel Fc Gamma-Binding 727 Glycoprotein in Rhesus Cytomegalovirus

Immune complexes inhibit 730 differentiation, maturation, and function of human monocyte-derived dendritic cells

Fc-Fusion Drugs Have 733

FcgammaR/C1q Binding and Signaling Properties That May Affect Their 734 Immunogenicity

Modulating 736 IgG effector function by Fc glycan engineering

Advances in the 739 understanding of the Fc gamma receptors-mediated autoantibodies uptake

Beyond binding: antibody effector 742 functions in infectious diseases

Fcgamma receptor cross-linking stimulates 744 cell proliferation of macrophages via the ERK pathway

Impact of immune complex size and 746 glycosylation on IgG binding to human FcgammaRs

Analysis of 748 viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus

Cytokine induction by 751 circulating immune complexes and signs of in-vivo complement activation in systemic 752 lupus erythematosus are associated with the occurrence of anti-Sjogren's syndrome A 753 antibodies

Mechanisms of immune complex-mediated 755 neutrophil recruitment and tissue injury

757 Expression of functional CD32 molecules on human NK cells is determined by an allelic 758 polymorphism of the FcgammaRIIC gene

760 Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins 761 to DC-SIGN by modification of N-linked glycans of envelope proteins

Fcgamma receptors: old friends and new family 764 members

Fcgamma receptors as regulators of immune 766 responses

Antibody-mediated modulation of immune 768 responses

Multiple Variables at the Leukocyte Cell 770 Surface Impact Fc gamma Receptor-Dependent Mechanisms

The stoichiometry of antibody-mediated neutralization and 773 enhancement of West Nile virus infection

Type I and type II Fc receptors regulate innate and adaptive 776 immunity

Subclass-specific IgG glycosylation is 779 associated with markers of inflammation and metabolic health

IgG Fc receptors

Conceptual Approaches to Modulating Antibody Effector Functions and 782 Circulation Half-Life

A CD153+CD4+ T follicular cell population with cell-785 senescence features plays a crucial role in lupus pathogenesis via osteopontin 786 production

Activation 788 of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that 789 induce autoreactive T cell responses

Antibody-Dependent Cellular Phagocytosis in 791

Hierarchical 795 and Redundant Roles of Activating FcgammaRs in Protection against Influenza 796 Disease by M2e-Specific IgG1 and IgG2a Antibodies

IgG subclasses and allotypes: from structure 801 to effector functions

Control of cytokine 803 production by human fc gamma receptors: implications for pathogen defense and 804 autoimmunity

Association of systemic lupus erythematosus with decreased 810 immunosuppressive potential of the IgG glycome

A plea for the pathogenic role of 812 immune complexes in severe Covid-19

Immune complexes: not just an innocent bystander in 814 chronic viral infection

Lupus-like syndrome attributable to anti-tumor necrosis 816 factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic

Suppression of Fcgamma-receptor-mediated 820 antibody effector function during persistent viral infection

Circulating and intra-articular immune complexes in patients with 823 rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological 824 features of the disease